Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vamifeport (VIT-2763) is a novel orally active inhibitor that targets iron transport proteins and reduces markers of hemolysis in the SCD Townes model.VIT-2763 improves anemia and erythropoiesis, ameliorates vascular inflammation, and can be studied in β-thalassemia.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 30,000 | |||
5 mg | 在庫あり | ¥ 72,500 | |||
10 mg | 在庫あり | ¥ 107,500 | |||
25 mg | 在庫あり | ¥ 176,500 | |||
50 mg | 在庫あり | ¥ 248,000 | |||
100 mg | 在庫あり | ¥ 333,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 87,500 |
説明 | Vamifeport (VIT-2763) is a novel orally active inhibitor that targets iron transport proteins and reduces markers of hemolysis in the SCD Townes model.VIT-2763 improves anemia and erythropoiesis, ameliorates vascular inflammation, and can be studied in β-thalassemia. |
In vitro | Treatment with VIT-2763 (20μM) or hepcidin (1μM) for 20 minutes, 1 hour, 3 hours, 6 hours, and 18 hours induced dose-dependent internalization and ubiquitination of iron transporters in MDCK cells[1]. |
In vivo | VIT-2763 (30, 100 mg/kg; orally twice daily for 36 days) restricted iron availability, ameliorating anemia and iron homeostasis dysregulation in the intermediate β-thalassemia Hbbth3/+ mouse model. VIT-2763 not only improved erythropoiesis but also corrected the proportion of myeloid precursors in the spleen of Hbbth3/+ mice[1]. |
別名 | VIT-2763 |
分子量 | 408.43 |
分子式 | C21H21FN6O2 |
CAS No. | 2095668-10-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 70 mg/mL (171.39 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Vamifeport 2095668-10-1 Apoptosis Ferroptosis VIT2763 VIT 2763 VIT-2763 Inhibitor inhibitor inhibit